Comparison · NCT00083174-7a8aa8e9
Randomization Period: Exemestane vs Randomization Period: Placebo: Incidence of All Clinical Fractures
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Randomization Period: Exemestane vs Randomization Period: Placebo: Incidence of All Clinical Fractures. Trial comparisons, record NCT00083174-7a8aa8e9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00083174-7a8aa8e9
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0665 | 0.0569 | 0.0776 | wilson | |
| Risk in group 2 | 0.0636 | 0.0542 | 0.0745 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00291 | -0.0116 | 0.0174 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.05 | 0.838 | 1.31 | log | |
| Odds ratio, group 1 over group 2 | 1.05 | 0.827 | 1.33 | log | |
| Number needed to treat, for one more participant with the outcome on Randomization Period: Exemestane than on Randomization Period: Placebo | 344 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Randomization Period: Exemestane | one 25 mg tablet daily in am | 149 | 2,240 | OG000 |
| Group 2 | Randomization Period: Placebo | one tablet daily in am | 143 | 2,248 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Incidence of All Clinical Fractures
- Description
- Time frame
- During protocol treatment over randomization period of study (up to 5 years)
- Population
- Women who have received treatment
Source ClinicalTrials.gov
Trial
- Title
- Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
- NCT number
- NCT00083174
- Phases
- PHASE3
- Conditions
- Breast Cancer
- Interventions
- exemestane
- Lead sponsor
- NCIC Clinical Trials Group
- Results first posted
- 2013-05-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00083174?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00083174-7a8aa8e9